REITHERA SRL, THE RAGON INSTITUTE AND IAVI ANNOUNCE COLLABORATION TO ADVANCE HIGHLY NETWORKED T CELL HIV VACCINE CANDIDATE TOWARDS PHASE I CLINICAL EVALUATION

 

 

Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by The
Bill & Melinda Gates Foundation to alleviate the disease burden and improve the lives of
the millions who lack access to prevention options.

ROME, Italy, NEW YORK and CAMBRIDGE, USA; JANUARY 22, 2023
ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to
announce a collaboration to develop a novel HIV vaccine candidate that will be composed of
ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by
the Bill & Melinda Gates Foundation.

Each partner will be responsible for a different aspect of the program:
• ReiThera will perform vector engineering and generation, process development, and
GMP manufacture and release for the clinical use of GRAd-HIV vaccine.
• The Ragon Institute will lead GRAd-HIV preclinical development.
• IAVI will be the sponsor and execute a phase I clinical trial to evaluate the safety and
immunogenicity of the GRAd-HIV vaccine candidate.

REITHERA SRL, THE RAGON INSTITUTE AND IAVI ANNOUNCE COLLABORATION TO ADVANCE HIGHLY NETWORKED T CELL HIV VACCINE CANDIDATE TOWARDS PHASE I CLINICAL EVALUATION

 

 

Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by The
Bill & Melinda Gates Foundation to alleviate the disease burden and improve the lives of
the millions who lack access to prevention options.

ROME, Italy, NEW YORK and CAMBRIDGE, USA; JANUARY 22, 2023
ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to
announce a collaboration to develop a novel HIV vaccine candidate that will be composed of
ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by
the Bill & Melinda Gates Foundation.

Each partner will be responsible for a different aspect of the program:
• ReiThera will perform vector engineering and generation, process development, and
GMP manufacture and release for the clinical use of GRAd-HIV vaccine.
• The Ragon Institute will lead GRAd-HIV preclinical development.
• IAVI will be the sponsor and execute a phase I clinical trial to evaluate the safety and
immunogenicity of the GRAd-HIV vaccine candidate.